Observations from cultured cells 1-3 , animal models 4 and patients 5-7 raise the possibility that the dependency of tumours on the therapeutic drugs to which they have acquired resistance represents a vulnerability with potential applications in cancer treatment. However, for this drug addiction trait to become of clinical interest, we must first define the mechanism that underlies it. We performed an unbiased CRISPR-Cas9 knockout screen on melanoma cells that were both resistant and addicted to inhibition of the serine/ threonine-protein kinase BRAF, in order to functionally mine their genome for 'addiction genes' . Here we describe a signalling pathway comprising ERK2 kinase and JUNB and FRA1 transcription factors, disruption of which allowed addicted tumour cells to survive on treatment discontinuation. This occurred in both cultured cells and mice and was irrespective of the acquired drug resistance mechanism. In melanoma and lung cancer cells, death induced by drug withdrawal was preceded by a specific ERK2-dependent phenotype switch, alongside transcriptional reprogramming reminiscent of the epithelial-mesenchymal transition. In melanoma cells, this reprogramming caused the shutdown of microphthalmia-associated transcription factor (MITF), a lineage survival oncoprotein; restoring this protein reversed phenotype switching and prevented the lethality associated with drug addiction. In patients with melanoma that had progressed during treatment with a BRAF inhibitor, treatment cessation was followed by increased expression of the receptor tyrosine kinase AXL, which is associated with the phenotype switch. Drug discontinuation synergized with the melanoma chemotherapeutic agent dacarbazine by further suppressing MITF and its prosurvival target, B-cell lymphoma 2 (BCL-2), and by inducing DNA damage in cancer cells. Our results uncover a pathway that underpins drug addiction in cancer cells, which may help to guide the use of alternating therapeutic strategies for enhanced clinical responses in drug-resistant cancers.
Figure 1 | Genome-wide CRISPR-Cas9 knockout screen to break cancer drug addiction identifies several signalling pathway components. a, BRAF mutant melanoma cells treated with 1 μM dabrafenib (451Lu cells) or 0.5 μM dabrafenib + 0.05 μM trametinib (A375, A101D and Mel888 cells) and stained 10 days later. b, BRAFi-resistant 451Lu BR cells were cultured with or without 1 μM dabrafenib; BRAFi + MEKi-resistant A375 BMR , A101D BMR and Mel888 BMR cells were cultured with or without 0.5 μM dabrafenib + 0.05 μM trametinib and stained after two (treated) or three weeks (untreated). c, d, Screen outline and hits for which the same target gene was found in more than two independent screen clones. e-h, Control cells and screen clones (as indicated), after dabrafenib or no treatment, were analysed by immunoblotting. KO, knockout. For gel source images, see Supplementary Fig. 1 . Data in a, b, e-h are representative of three independent biological experiments.
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For nine of these, we identified single-guide RNAs (sgRNAs) for the same gene in two or more individual clones ( Fig. 1d ; for full sequencing data, see Supplementary Table 1) ; these sgRNAs targeted genes that encode several factors known to communicate with one another, namely ERK2, JUNB and MEK1. We also included FRA1, a partner of JUNB, in further analyses. A first validation round confirmed that the sgRNAs had caused the expected perturbations of genes encoding ERK2 (with intact ERK1; Fig. 1e ), JUNB ( Fig. 1f ), MEK1 (with intact MEK2; Fig. 1g ) and FRA1 (Fig. 1h ). This genome-wide perturbation screen was therefore able to successfully identify a signalling pathway responsible for the drug addiction phenotype.
To determine whether these screen hits operated in a general fashion, we used a panel of melanoma cell lines that had acquired drug resistance through distinct mechanisms: 451Lu BR cells showed hyperactivation of the ERK pathway (Extended Data Fig. 2a ) and harboured a MEK1 K57N -activating mutation ( Fig. 2a ); A375 BMR cells, which carry a BRAF amplification, also displayed boosted MEK-ERK signalling ( Fig. 2b and Extended Data Fig. 2b, c) ; and Mel888 BMR cells showed hyperactivated MEK-ERK signalling and harboured a kinase domain duplication ( Fig. 2c and Extended Data Fig. 2d ), as recently described 9 . By contrast, A101D BMR cells acquired drug resistance without detectable ERK reactivation (Fig. 2d ).
In control drug-addicted melanoma cells, drug withdrawal was accompanied by massive cell death; however, knocking out MAPK1 (encoding ERK2) resulted in a vigorous rescue across the entire cell panel ( Fig. 2e, f) . By contrast, genetic perturbation of MAPK3 (encoding ERK1) failed to prevent drug addiction. As with ERK2, inactivation of JUNB ( Fig. 2g , h) or loss of FOSL1 (encoding FRA1; Fig. 2i , j) generally rescued the cell death associated with withdrawal in drug-addicted cells. Knocking out MAP2K1 (encoding MEK1) also prevented drug addiction, but only in 451Lu BR cells (Extended Data Fig.  3a , b); the resistance mechanism of this cell line, a MEK1 K57N -activating mutation (Figs 1g, 2a), renders it susceptible to breaking drug addiction upon loss of MEK1. The ERK2-JUNB-FRA1 pathway was, therefore, validated across a heterogeneous cell line panel, suggesting a common mechanism of action for drug addiction, which is independent of how cells achieve therapy resistance.
To determine whether the drug addiction phenotype manifests in vivo, we established melanoma xenografts in mice in the presence of both dabrafenib and trametinib. When treatment ceased, control tumours regressed; JUNB and ERK2-knockout tumours, however, continued to expand ( Fig. 2k ), indicating that the drug addiction phenotype is also seen in tumours.
These findings implicated ERK2 signalling in the sensitivity of drug-resistant cells to treatment discontinuation. In 451Lu BR , A375 BMR and Mel888 BMR cells, we observed hyperactivation of MEK-ERK signalling upon drug withdrawal, a so-called rebound signal (Extended Data Fig. 4a ). A101D BMR cells, which have acquired resistance to BRAF-MEK inhibition in an ERK-independent fashion (Fig. 2d ), showed an equally intense ERK rebound upon drug washout. This result suggests that the mechanism of acquiring drug resistance is uncoupled from the signalling pathway that manifests drug addiction. sgRNA. Cells were cultured with or without drugs, and stained (e, g, i) or immunoblotted (f, h, j). k, A375 BMR cells ablated for the indicated genes were subcutaneously injected into both flanks of immune-deficient NOD/SCID-gamma (NSG) mice. Mice (n = 5 per group) received 30 mg kg −1 dabrafenib and 0.3 mg kg −1 trametinib from the first day of tumour cell injection onward. After seven days, treatment was discontinued for all mice. The graph represents fold change in tumour volume, normalized to tumour volume on the day of treatment discontinuation. Data in graphs are mean ± s.e.m. *** P < 0.001 by unpaired two-sided Student's t-test. For tumour volume measurements, see Supplementary  Table 3 . For gel source images, see Supplementary Fig. 1 . Data in b-j are representative of three independent biological experiments.
Corroborating these findings, a low dose of ERK inhibitor completely prevented lethality stemming from drug withdrawal, not only in the three cell lines with ERK rebound (consistent with previous results 3 ) but also in A101D BMR cells (Extended Data Fig. 4b ). Thus, regardless of the resistance mechanism, melanoma cells show ERK rebound upon drug withdrawal, which contributes to the drug addiction trait.
As our screen identified two key signalling transcription factors (JUNB and FRA1), we investigated whether drug addiction is relayed by transcriptional reprogramming. RNA profiling of drug-addicted cells after drug cessation revealed a common expression alteration for the top 200 variant genes in two cell lines (Extended Data Fig. 5a ). This was accompanied by a major switch in the activity of genes involved in cell proliferation and in those contributing to cell invasion, reminiscent of changes seen for phenotype switching (transcriptional and phenotypic plasticity between alternative proliferative and invasive states) [10] [11] [12] (Fig. 3a) .
MITF is a pivotal transcription factor that drives the specification and survival of the melanocytic lineage 13 and has a central role in melanoma phenotype switching 11 . Gene set enrichment analysis (GSEA) revealed a strong negative association between drug withdrawal and MITF signature ( Fig. 3b ), with many MITF targets being strongly downregulated upon drug withdrawal. GSEA confirmed that the transcriptional signatures of AP-1, TEAD and JUNB 14 were enriched upon drug withdrawal (Extended Data Fig. 5b ), further supporting the notion that drug-addicted cells underwent phenotype switching after drug withdrawal.
MITF protein levels concordantly declined upon drug withdrawal in all four cell lines examined ( Fig. 3c ). As a result, both the MITFcontrolled Melan-A and BCL-2 proteins were downregulated. Drug withdrawal was also associated with the upregulation of fibronectin and downregulation of E-cadherin, two EMT proteins. MITF expression has recently been shown to be inversely correlated with the expression of the receptor tyrosine kinase AXL 15, 16 . Consistent with this, AXL was induced by drug removal, as were JUNB and FRA1 (Fig. 3c ).
By contrast, although cJUN can mediate a melanoma phenotype switch upon BRAF inhibition and cytokine treatment 17, 18 , it was not strongly or consistently induced by drug removal (Fig. 3c ); its ablation failed to prevent cell death induced by drug withdrawal (Extended Data Fig. 5c, d ). Upon drug withdrawal, cells became highly migratory, which is another key feature of EMT (Extended Data Fig. 5e , f). Finally, the phenotype switch was not seen in cells that were not drug-addicted (Extended Data Fig. 6a , b).
To investigate whether this phenotype switch could be recapitulated in a clinical setting, we performed immunohistochemical analysis on a set of tumour biopsies from patients with melanoma who had experienced BRAFi relapse. This cohort of biopsies comprised tumours from patients who were still on BRAFi treatment at the time of the biopsy, as well as patients who had already been taken off the drug. We observed that in a highly significant number of cases, treatment discontinuation was correlated with increased AXL expression ( Fig. 3d ), indicating that at least some features of EMT or phenotype switching can also be observed in a clinical setting.
To examine a potential contribution of MITF to the phenotype switch, we restored its expression by introducing an MITF cDNA into drug-addicted 451Lu BR and A101D BMR cells ( Fig. 3e ). MITF was at least partially functional, as judged by the attenuation of Melan-A downregulation on drug washout. Restoring MITF substantially protected cells from death by drug withdrawal (Fig. 3f ), demonstrating that drug addiction is accompanied by an MITF-dependent phenotype switch, which underlies the associated loss of fitness.
To determine whether the screen hits were functionally connected to phenotype switching, we generated pools of ERK2 and JUNB knockout cells and performed RNA sequencing before and after drug withdrawal. This revealed a shift in transcriptional patterns, notably phenotype switch genes, in control cells that was diminished in the ERK2 knockout derivatives and, to a lesser extent, in the JUNB knockout cells (Extended Data Fig. 7a, b ). The prevention of drug washout-induced cell death by means of ERK2 or JUNB depletion was strongly correlated Melan-A + GP100
Colour key and histogram Letter reSeArCH with maintenance of the MITF signature, and a lack of AP-1, TEAD and JUNB signatures (Extended Data Fig. 7c ). As a consequence, the phenotypic changes in cell morphology after drug withdrawal were neutralized in the ERK2 and JUNB knockout cell lines, but not in ERK1 knockout cells ( Fig. 3g ).
To investigate whether ERK2 is a master regulator of this phenotype switch, we analysed the expression of several proteins associated with this process. Following the loss of ERK2, MITF and its downstream targets BCL-2 and Melan-A were no longer downregulated after drug removal (Fig. 3h ). Furthermore, the induction of JUNB and FRA1 after drug withdrawal was diminished in ERK2 knockout cells (but not in ERK1 knockout cells). The ablation of JUNB, too, prevented the decline in MITF after drug withdrawal, but did not affect ERK levels or activity; this suggests that JUNB acts downstream of ERK and upstream of MITF. As judged by their expression of fibronectin and E-cadherin, cells that lacked ERK2 or JUNB, but not ERK1, failed to undergo EMT-like changes following drug withdrawal. In addition, pharmacological inhibition of ERK neutralized the changes in gene expression (Extended Data Fig. 8a ) and cell morphology (Extended Data Fig. 8b ) that were otherwise observed after drug withdrawal.
We corroborated these in vitro observations with in vivo experiments. Established control A375 BMR tumours (Fig. 2k ) were largely negative for MITF and its targets, Melan-A and glycoprotein 100 (GP100), after drug discontinuation. By contrast, JUNB or ERK2 knockout melanomas retained their expression of MITF and its targets (Fig. 3i ). These results demonstrate that ERK2 and JUNB act in an MITF-dependent genetic phenotype switching programme that governs drug addiction.
Increasing ERK1 and ERK1 phosphorylation to similar levels to those seen for ERK2 after drug removal failed to cause cell death in the absence of ERK2. This suggests that ERK2 functions distinctly from ERK1 in the context of drug addiction (Extended Data Fig. 9a, b ) and is consistent with their separate activities in EMT 19 . In addition to acquired resistance, tumour cells with enforced BRAFi resistance (by ectopic expression of mutant MEK1 T55delinsRT ; ref. 20) also experienced declines in viability, and in levels of MITF and its targets, after drug withdrawal (Extended Data Fig. 8c, d) .
Because acquired resistance to precision drugs is common across a range of tumour types and drugs, we investigated whether the drug addiction mechanism identified here was also operational in lung cancer. After drug withdrawal, HCC827 cells that were both refractory and addicted to the epidermal growth factor receptor (EGFR) inhibitor CL-387785 experienced a loss of fitness 1 (Fig. 4a ). As with melanoma cells, pharmacological (Extended Data Fig. 8e ) or genetic ablation of ERK2 (but not ERK1) reversed the drug addiction of these non-small cell lung cancer cells (Fig. 4a, b ). Several events preceded this loss of fitness caused by drug withdrawal, including hyperactivation of ERK and MEK, and an EMT/phenotype switch-like reprogramming (Fig. 4c) ; these were also observed for melanoma cells. We conclude that the ERK2-JUNB-FRA1 pathway responsible for drug addiction in melanoma cells is not limited to a particular tumour or treatment setting.
The extent of lethality imposed by drug addiction can be near total, and produced the very low background of clones in the control arm of our screen (Fig. 1b) . Over time, however, clones that were resistant to drug withdrawal spontaneously arose from cell pools (Extended Data Fig. 10a ). Functional and biochemical analyses (Extended Data Fig. 10b , c) revealed that they had regained responsiveness to MAPK pathway inhibition. This is consistent with the fact that clinical rechallenges with inhibitors targeting the MAPK pathway in patients whose cancer has progressed on treatment are sometimes successful 21, 22 .
In clinical settings, the emergence of cells that are resistant to drug withdrawal could prevent lasting clinical responses. Therefore, we considered whether combining the cessation of BRAF inhibition with the initiation of another treatment could enhance the durability of these responses. In the past decade, the chemotherapeutic agent dacarbazine (known by the brand name DTIC), an anticancer alkylating agent, has been commonly used as a single agent for metastatic melanoma, albeit with poor response rates 23 . We sought to determine whether dacarbazine treatment acts cooperatively with a discontinuation of treatment with BRAFi, and whether it could therefore be used in an alternating therapy strategy. Dacarbazine concentrations of up to 500 μg ml −1 had little cytotoxic effect on two drug-resistant and modera tely drug-addicted melanoma cell lines in the presence of BRAFi (Fig. 4d) . By contrast, when dacarbazine was administered after the BRAFi had been withdrawn, the cytotoxic effects were greatly increased. This was accompanied by the synergistic induction of γH2AX, a marker of double-stranded DNA damage (Fig. 4e ) and a cooperative suppression of MITF and its targets Melan-A and BCL-2 (Fig. 4e) . The reduction in the levels of the BCL-2 prosurvival protein, combined with the induction of DNA damage, provides a plausible mechanism for the observed synergy between BRAFi withdrawal and dacarbazine treatment in inducing cell death.
Alternating or intermittent therapeutic strategies may create larger therapeutic windows 21, [24] [25] [26] than do continuous treatments with single agents. Because clones that have acquired resistance to drug withdrawal can emerge after a long drug 'holiday' , we suggest that rather than simply halting drug treatments for a set period, therapeutic strategies should c, HCC827 CLR cells were cultured with or without CL-387785 for the indicated amount of time and immunoblotted. d, e, Moderately drugaddicted D10 BR and A375 BR melanoma cells were cultured in the presence of the indicated concentrations of dabrafenib and dacarbazine and stained ten days later (d) or immunoblotted (e). For gel source images, see Supplementary Fig. 1 . Data in a-e are representative of three independent biological experiments. f, Model for the ERK2-dependent phenotype switch that drives cancer drug addiction, in the context of drug pressure and resistance (left), and drug withdrawal causing addiction-associated lethality, irrespective of drug resistance mechanism (right). Grey symbols indicate other potential signalling pathways involved in drug resistance and drug addiction.
Letter reSeArCH explore optimal alternating treatment modalities. Our results suggest that by developing a more detailed understanding of the molecular mechanism of drug addiction (which seems to be conserved among different tumour types and targeted agents), we may be able to design alternating treatment strategies that enhance mortality among drugresistant cells after drug withdrawal, producing more durable clinical benefits.

MethOdS
No statistical methods were used to predetermine sample size. Unless otherwise stated, the experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. GeCKO screen. Drug-addicted 451Lu BR cells were lentivirally transduced with two GeCKO libraries (A and B) 8 . Two days after infection, cells were selected with puromycin (2 μg ml −1 ) for three days. Cells were split into two pools; one was subjected to BRAFi dabrafenib (1 μM) treatment, and the other was left untreated. Cell colonies that formed in the drug-deprived group were individually picked and expanded. For identification of sgRNAs in individual clones, genomic DNA was isolated and sgRNAs were recovered by PCR amplification. Amplified DNA fragments were cloned into the TOPO TA-cloning vector (450071, Invitrogen), and the sgRNA was identified using Sanger sequencing. Compounds. The BRAF inhibitors dabrafenib and PLX4720, the MEK inhibitor trametinib, the ERK inhibitor SCH772984 and the EGFR TKI CL-387785 were purchased from Selleck Chemicals. Dacarbazine was obtained from the pharmacy of the Slotervaart hospital. Cell lines. A375, Mel888, A101D, SK-Mel-28, D10 and HEK293T cells were from the Peeper laboratory cell line stock. HCC827 and HCC827 CLR cells were from K. Suda and T. Mitsudomi (Kindai University) and 451Lu cells from J. Villanueva (The Wistar Institute). All cell lines were authenticated by STR profiling (Promega) and routinely tested for mycoplasma contamination. All cell lines were cultured in DMEM supplemented with 9% fetal bovine serum (Sigma), plus 100 units per ml penicillin and 0.1 mg ml −1 streptomycin (Gibco). To generate BRAFi or BRAFi + MEKi-resistant cells, parental drug-sensitive cells were exposed to increasing concentrations of BRAFi dabrafenib (from 0.01 μM to 5 μM) or BRAFi dabrafenib + MEKi trametinib (from 0.01 μM + 0.001 μM to 0.5 μM + 0.05 μM) for 3-5 months. PLX4720-resistant cells were generated as previously described 16 . The resistance was confirmed by measuring cell viability under drug treatment. Colony formation assay. Colony formation assays were performed in 12-well plates by seeding 3,000 cells (A101D BMR ), 10,000 cells (HCC827 CLR , SK-Mel-28 BR , Mel888 PLXR , A375 PLXR A375 WR , 451Lu WR , A101D WR and all parental drugsensitive cells), 30,000 cells (Mel888 BMR ), or 50,000 cells (451Lu BR , A375 BMR , A375 BR , D10 BR and D10 BMR ). Medium was refreshed twice per week and plates were fixed in 4% formaldehyde solution, stained with crystal violet (1% in 50% methanol) and photographed after 10-21 days of treatment (as indicated). Animal studies. Animal work procedures were approved by the animal experimental committee of the NKI and performed according to Dutch law. The in vivo experiment was performed with A375 BMR cells infected with lentivirus encoding sgRNAs. Cells (10 6 ) were injected subcutaneously into both flanks of 5-7-week-old female NSG mice. The mice received dabrafenib and trametinib by daily oral gavage, from the first day of tumour injection until drug treatment was stopped. Tumour growth rates were analysed by measuring tumour length (L) and width (W), and calculating volume through the use of the formula LW 2 /2. Human melanoma specimens. Patient melanoma samples were obtained (following Institutional Review Board approval) from the NKI-AVL pathology archive biobank. Informed consent was obtained from all patients. Immunohistochemistry and scoring. AXL staining was performed manually. After deparaffinization of FFPE-fixed slides using xylene, antigen retrieval was performed using citrate buffer (pH 6) in a pressure cooker for 5 min. Sections were treated with 0.3% H 2 O 2 to block endogenous peroxidase activity and sub sequently blocked in 10% human serum in PBS-T for 30 min. Primary AXL antibody (sc-20741, Santa Cruz) was applied at a concentration of 3 μg ml −1 for 1 hour at room temperature. Detection was performed with an anti-rabbit HRP-conjugated antibody (Immunologic, Brightvision) and developed using AEC and a counterstain of haematoxylin. Slides were manually analysed by a certified pathologist from the VU Medical Center in a blinded fashion. The percentage of AXL positive cells was determined by analysing whole slides of every sample. MITF (clone C5/D5, Immunologic), Melan-A and GP100 (ab732, Abcam) stainings in mouse xenograft tumours were performed using the protocol described above, with minor modifications (they were blocked with goat serum, incubated with anti-mouse HRP-conjugated antibody and developed with DAB). Immunoblotting. Immunoblotting was performed as previously described 16 . The following antibodies were used: pERK1/2 (Thr202/Tyr204, 9106), ERK1/2 (9102), pMEK1/2 (Ser217/221, 9154), MEK1/2 (4694), MEK1 (2352), MEK2 (9147), JUNB (3753), pFRA1 (Ser265, 5841), p-cJUN (Ser73, 3270) and cJUN (2315) BCL-2 (4223) from Cell Signaling Technology; BRAF V600E (E19290) from Spring Bioscience; ATK (sc-8312), pAKT (Ser473, sc-7985-R), FRA1 (sc-28310), BRAF (sc-5284), BCL-2 (sc-492) and HSP90 (sc-7947) from Santa Cruz Biotechnology; MITF (ab12039) and AXL (ab89224) from Abcam; Melan-A (M7196) from Dako; E-cadherin (610181), Vimentin (550513) and Fibronectin (610077) from BD Bioscience. The antibodies were diluted according to manufacturers' instructions. Fluorescence in situ hybridization. Preparation of metaphase chromosome spreads from A375 and A375 BMR cells was performed as previously described 27 . Two-colour metaphase FISH was performed using a BRAF probe (7q34 BRAF-CN RD, G100368R-8, Agilent) and a probe located on the chromosome 7 centromere (Chr7 CEP GR, G100527G-8, Agilent), according to the manufacturer's protocol. PCR, Sanger sequencing, cloning and lentivirus production. All primer sequences are listed in Supplementary Table 2 . For identification of BRAF amplification in A375 BMR cell, genomic DNA was isolated and quantitative PCR was performed with primers amplifying BRAF, CRAF and LINE. For identification of the MAP2K1 mutation in 451Lu BR cells, genomic DNA was isolated and MAP2K1 exon 2 was cloned into the TOPO TA-cloning vector (450071, Invitrogen), followed by Sanger sequencing. The presence of BRAF V600E/DK in Mel888 BMR cells was identified as previously described 9 . For construction of an sgRNA-expressing vector, DNA oligonucleotides (Invitrogen) were annealed and ligated into BsmBIdigested LentiCRISPRv2 plasmid. Target sgRNA oligonucleotide sequences are listed in Supplementary Table 2 . The plasmid encoding the MITF-M isoform has been previously described 16 . Production of lentivirus was performed as previously described 28 . Transwell migration assay. To examine the migration potential, cells were cultured in the presence or absence of MAPK pathway inhibitors for 1 day followed by seeding 200,000 cells into the top chambers of a transwell (3422, Corning) in serum-free medium, with or without inhibitors. The lower compartment contained medium supplemented with 9% fetal bovine serum as a chemoattractant. Cells were incubated for 8 (A101D BMR ) or 24 (451Lu BR ) hours and cells that did not migrate through the pores were removed with a cotton swab. Filters were fixed in 4% formaldehyde solution, stained with 0.1% crystal violet and photographed, and then cells were counted. RNA sequencing analysis. RNA was isolated using Trizol, and cDNA libraries were sequenced on an Illumina HiSeq2000 to obtain 65-bp single-end sequence reads. Reads were aligned to the GRCh38 human reference genome using TopHat (2.1.0), and gene counts were obtained using HTSeq-count. All downstream analyses were performed in R using the Bioconductor framework. DESeq2 rlog-values were used for visualization of gene expression levels in heat maps. Heat maps represent mean rlog-values of two independent biological replicate experiments. Clustering was performed using the default settings of the heatmap.2 function in the gplots package. For Extended Data Fig. 5a , gene-wise scaling was applied to rlog-values; the 200 most variable values are represented. For Fig. 3a and Extended Data Fig. 7a, b , rlog-values were mean normalized on a gene-wise basis. For GSEAs, counts per million were used as input. For Fig. 3b and Extended Data Fig. 5b , time points were converted to a ranking score (0, 1, 2 and 3 for time points 0, 6, 24 and 48 hours of A375 BMR or 0, 1, 3 and 5 days of 451Lu BR , respectively). For Extended Data Fig.  7c , the extent of rescue from cell death was converted to a ranking score (1, 2, 3, or 4 for Mel888 BMR cells expressing sgCtrl, sgJUNB, or sgERK2 in the context of drug removal, and Mel888 BMR cells with treatment, respectively). Pre-ranked gene lists were created by correlating these ranking scores with gene expression using the Spearman's rank correlation coefficient metric. Phenotype switching and MITF target gene lists were obtained from http://www.jurmo.ch/work_mitf.php. The TEAD and AP1 signatures were taken from ref. 14, and the JUNB signature was derived from supplementary table 3a of ref. 29 , where human homologues of mouse genes were derived using the biomaRt package. Analyses were performed using javaGSEA 30 and replotted from the output of this tool using the replotGSEA function (https://github.com/PeeperLab/Rtoolbox). Data availability. All sequencing datasets have been deposited in the NCBI Gene Expression Omnibus under accession numbers GSE98866 and GSE98867. 
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Extended Data Figure 7 | ERK2 and JUNB act in an MITF-dependent genetic phenotype switching program controlling drug addiction. a, Mel888 BMR cells were infected with lentivirus expressing sgRNAs targeting genes encoding JUNB (sgJUNB), ERK2 (sgERK2) or a scrambled sequence (sgCtrl). Cells were cultured in the presence or absence of 0.5 μM BRAFi + 0.05 μM MEKi for five days. Total RNA was isolated and subjected to sequencing analysis. Unsupervised clustering of the 200 most variably expressed genes is represented in a heat map. b, Genes involved in phenotype switching were selected from the sequence data in a and are represented in a heat map. c, Sequence data in a were subjected to GSEA to determine the correlation of the indicated gene sets with the extent of rescue of the drug addiction phenotype by sgJUNB and sgERK2 in Mel888 BMR cells. dw, drug withdrawal. For P value calculation, see Methods.
Extended Data Figure 9 | ERK2 and ERK1 have distinct functions in drug addiction. a, 451Lu BR control cells (sgCtrl), ERK2 knockout cells (sgERK2), ERK1 (v5-tagged)-overexpressing sgERK2 cells (sgERK2, ERK1 OE) and ERK1 knockout cells (sgERK1) were cultured in the presence or absence of 1 μM BRAFi for up to six days. Total cell lysates were subjected to immunoblotting analysis with indicated antibodies.
HSP90 served as a loading control. b, Cells described in a were cultured in the presence or absence of BRAFi, and fixed, stained and photographed after 14 days (BRAFi group) or 21 days (no drug group). For gel source images, see Supplementary Fig. 1. Data in a and 
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